Physician profile
Robert K Dean
NPI 1659418325
$6,108.86
in general payments reported to CMS, 2019-2025
32 companies · $73.24 in 2025
The $73.24 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $913 · 2020: $655 · 2021: $2,210 · 2022: $2,035 · 2023: $99.23 · 2024: $123 · 2025: $73.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $295.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,363.01 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $1,250.00 | 2022 | |
| Novo Nordisk INC | $684.20 | 2019-2025 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $395.76 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $311.68 | 2019-2022 | |
| Pfizer INC. | $295.10 | 2019-2021 | |
| Abbott Laboratories | $281.86 | 2019-2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.87 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $170.50 | 2019-2022 | |
| Antares Pharma, INC. | $163.21 | 2019-2022 | |
| Lilly USA, LLC | $158.01 | 2019-2022 | |
| Abbvie INC. | $105.34 | 2021-2022 | |
| Eisai INC. | $98.24 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $69.65 | 2019-2020 | |
| Amarin Pharma, INC. | $67.12 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $60.00 | 2020 | |
| Glaxosmithkline, LLC. | $47.82 | 2019-2021 | |
| Genentech USA, INC. | $43.27 | 2021 | |
| Adlon Therapeutics L.P. | $42.26 | 2021 | |
| Neos Therapeutics, LP | $40.62 | 2019 | |
| Amgen INC. | $36.53 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $31.04 | 2019-2020 | |
| Acerus Pharmaceuticals Corporation | $24.90 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $24.69 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $19.60 | 2022 | |
| Ironshore Pharmaceuticals INC. | $18.50 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.09 | 2022 | |
| Shire North American Group INC | $17.65 | 2019 | |
| Esperion Therapeutics, INC. | $17.63 | 2020 | |
| Allergan, INC. | $14.91 | 2020 | |
| Horizon Therapeutics Plc | $12.33 | 2019 | |
| Endo Pharmaceuticals INC. | $11.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.